BIOTECHNOLOGY VALUE FUND L P 4
4 · Kymera Therapeutics, Inc. · Filed Jun 26, 2026
Research Summary
AI-generated summary of this filing
Kymera (KYMR) BVF Partners L.P. Sells $173.7M Shares
What Happened
BVF Partners L.P. (part of a group of BVF entities that filed jointly and tied to a Kymera director by footnote) disposed of a total of 1,630,658 shares of Kymera Therapeutics (KYMR) in open-market sales on June 26, 2026. The sales occurred in four blocks at $106.50 per share: 837,914 shares ($89,237,841), 627,597 shares ($66,839,081), 113,289 shares ($12,065,279), and 51,858 shares ($5,522,877), for aggregate proceeds of $173,665,078. These transactions are coded as S (sales).
Key Details
- Transaction date and price: 2026-06-26, all sales at $106.50 per share.
- Total shares sold: 1,630,658; total proceeds: $173,665,078 (~$173.7M).
- Shares owned after transaction: Not specified in the excerpt provided.
- Filing date: Form 4 filed 2026-06-26 (appears to be same-day/timely reporting).
- Notable footnotes: joint filing by multiple BVF entities (F1–F5); sellers disclaim direct beneficial ownership except for pecuniary interests; sales are linked to Partners and an agreement with director Gorjan Hrustanovic who may transfer economic benefit to Partners (F7, Remarks).
- Transaction type: Open-market cash sales (S). No option exercises or awards reported in these trades.
Context
These are institutional/investment-fund sales rather than a straightforward executive personal sale — the filing lists multiple BVF-related entities and notes that beneficial ownership is claimed only to the extent of pecuniary interest. Sales by funds or affiliated entities can be for portfolio rebalancing or liquidity and do not necessarily signal management views on company fundamentals. As always, retail investors should combine insider activity with other fundamentals and disclosures before drawing conclusions.
Insider Transaction Report
Form 4
BVF PARTNERS L P/IL
DirectorOther
Transactions
- Sale
Common Stock, $0.0001 par value
[F1][F2]2026-06-26$106.50/sh−837,914$89,237,841→ 1,960,881 total - Sale
Common Stock, $0.0001 par value
[F1][F3]2026-06-26$106.50/sh−627,597$66,839,081→ 1,592,261 total - Sale
Common Stock, $0.0001 par value
[F1][F4]2026-06-26$106.50/sh−113,289$12,065,279→ 240,123 total - Sale
Common Stock, $0.0001 par value
[F1][F5]2026-06-26$106.50/sh−51,858$5,522,877→ 78,787 total(indirect: See footnote)
Holdings
- 201,546
Pre-Funded Warrants to Purchase Common Stock
[F1][F6][F2]Exercise: $0.00→ Common Stock, $0.0001 par value (201,546 underlying) - 156,742
Pre-Funded Warrants to Purchase Common Stock
[F1][F6][F3]Exercise: $0.00→ Common Stock, $0.0001 par value (156,742 underlying) - 550,425
Pre-Funded Warrants to Purchase Common Stock
[F1][F6][F2]Exercise: $0.00→ Common Stock, $0.0001 par value (550,425 underlying) - 375,856
Pre-Funded Warrants to Purchase Common Stock
[F1][F6][F3]Exercise: $0.00→ Common Stock, $0.0001 par value (375,856 underlying) - 52,733
Pre-Funded Warrants to Purchase Common Stock
[F1][F6][F4]Exercise: $0.00→ Common Stock, $0.0001 par value (52,733 underlying) - 27,797(indirect: See footnote)
Pre-Funded Warrants to Purchase Common Stock
[F1][F6][F5]Exercise: $0.00→ Common Stock, $0.0001 par value (27,797 underlying) - 40,127(indirect: See footnote)
Stock Option (Right to Buy)
[F7][F8]Exercise: $20.00Exp: 2030-08-19→ Common Stock, $0.0001 par value (40,127 underlying) - 20,063(indirect: See footnote)
Stock Option (Right to Buy)
[F7][F8]Exercise: $49.10Exp: 2031-06-15→ Common Stock, $0.0001 par value (20,063 underlying) - 12,000(indirect: See footnote)
Stock Option (Right to Buy)
[F7][F8]Exercise: $14.18Exp: 2032-06-14→ Common Stock, $0.0001 par value (12,000 underlying) - 12,000(indirect: See footnote)
Stock Option (Right to Buy)
[F7][F8]Exercise: $27.67Exp: 2033-06-14→ Common Stock, $0.0001 par value (12,000 underlying) - 16,000(indirect: See footnote)
Stock Option (Right to Buy)
[F7][F8]Exercise: $31.20Exp: 2034-06-17→ Common Stock, $0.0001 par value (16,000 underlying) - 16,000(indirect: See footnote)
Stock Option (Right to Buy)
[F7][F8]Exercise: $46.47Exp: 2035-06-24→ Common Stock, $0.0001 par value (16,000 underlying) - 6,068(indirect: See footnote)
Stock Option (Right to Buy)
[F7][F9]Exercise: $99.87Exp: 2036-06-23→ Common Stock, $0.0001 par value (6,068 underlying)
Footnotes (9)
- [F1]This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
- [F2]Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
- [F3]Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
- [F4]Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
- [F5]Securities held in a certain Partners managed account (the "Partners Managed Account"). Partners may be deemed to have indirect beneficial ownership of the securities of the Issuer held by the Partners Managed Account for purposes of Rule 16a-1(a)(2) because the securities account for more than 10% of the market value of the portfolio of the Partners Managed Account as of the reporting date. Partners, as the investment manager of the Partners Managed Account, may be deemed to beneficially own the securities held by the Partners Managed Account. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Account. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Account.
- [F6]The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to certain conditions and limitations, and do not expire.
- [F7]Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- [F8]The shares subject to the option have fully vested.
- [F9]The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.